What is KPTI's current stock price?

KPTI (Karyopharm Therapeutics Inc.) is currently trading at $8.16 with a market cap of $69.7M.

What sector is Karyopharm Therapeutics Inc. in?

Karyopharm Therapeutics Inc. (KPTI) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is KPTI a good stock to buy?

Analysts have a Buy consensus on KPTI with a price target of $17.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

KPTI Karyopharm Therapeutics Inc.

Healthcare

$8.16+1.24%ClosedMarket Cap: $69.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-0.68

P/S

0.46

EV/EBITDA

-1.27

DCF Value

$-76.34

FCF Yield

-84.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

96.0%

Operating Margin

-55.7%

Net Margin

-129.0%

ROE

73.1%

ROA

-148.4%

ROIC

-177.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$35.1M	$-22.4M	$—
Q4 null	$34.1M	$-102.2M	$—
FY null	$146.1M	$-196.0M	$—
Q3 null	$44.0M	$-33.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.25

Target (Median)

$14.50

Target Range

$12.00 - $28.00

2 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-06

Piper SandlerOverweight

2026-04-27

HC Wainwright & Co.Buy

2026-03-25

BairdOutperform

2026-03-25

HC Wainwright & Co.Buy

2026-02-18

Trading Activity

Insider Trades

View All

Rangwala Reshmaofficer: EVP & Chief Medical Officer

SellFri May 15

Rangwala Reshmaofficer: EVP & Chief Medical Officer

SellFri May 15

Poulton Stuartofficer: EVP, Chief Development Officer

SellFri May 15

Poulton Stuartofficer: EVP, Chief Development Officer

SellFri May 15

Paulson Richard A.director, officer: President and CEO

SellFri May 15

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.81

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Peers

CVM